The partnership is based on Genome & Company's oncology drug pipeline and Debiopharm's track record in oncology, with its colorectal cancer and prostate cancer drugs, oxaliplatin and triptorelin. Genome & Company will incorporate Debiopharm's Multilink antibody-drug conjugate technology, which enables high drug-to-antibody ratio, into its Gnocle drug discovery platform, which will enable clinicians to deliver cancer killing treatment to tumor cells.

Debiopharm also offers AbYlink, which attaches cancer-killing fragment crystallizable (Fc)-selective attachment of cargos, such as radioactive agents, or fluorophores to antibodies, it said.

Surface Oncology licenses anti-cancer antibody from Vaccinex
Surface Oncology will exercise an option to license an anti-C-C motif chemokine receptor 8 antibody discovered using the ActivMab antibody discovery and...

ImmunoPrecise SARS-CoV-2 antibody cocktail successful in preclinical models
ImmunoPrecise Antibodies has demonstrated that its proprietary TATX-03 PolyTope antibody cocktail against SARS-CoV-2 provides complete clearance of replication-competent...

Nucleai and Debiopharm team up for cancer drug development
Biomarker discovery company Nucleai will work with Swiss pharmaceutical developer Debiopharm to optimize development of a clinical oncology asset per...

Flywheel, AIQ to offer cancer therapy response system
Flywheel and AIQ Solutions have partnered to offer a data management and analysis system aimed at boosting scientists' understanding of treatment responses...